Table 1.
Patient demographics and baseline characteristics
| Characteristic | Multitarget, n=116 | AZA, n=90 | Total, n=206 |
|---|---|---|---|
| Sex, women/men | 108/8 | 81/9 | 189/17 |
| Age, yr | 30.0 (24.0, 38.0) | 33.0 (26.0, 40.0) | 32.0 (24.0, 39.0) |
| Pathologic classification, n (%) | |||
| Class III | 5 (4.3) | 7 (7.8) | 12 (5.8) |
| Class IV | 50 (43.1) | 39 (43.3) | 89 (43.2) |
| Class V | 14 (12.1) | 12 (13.3) | 26 (12.6) |
| Class III+V | 15 (12.9) | 2 (2.2) | 17 (8.3) |
| Class IV+V | 32 (27.6) | 30 (33.3) | 62 (30.1) |
| Remission condition (%)a | |||
| CR | 69 (59.5) | 40 (44.4) | 109 (52.9) |
| PR | 47 (40.5) | 50 (55.6) | 97 (47.1) |
| SLEDAIa | 4.0 (2.0, 4.5) | 4.0 (2.0, 6.0) | 4.0 (2.0, 6.0) |
| Urinary protein, g/24 ha | 0.35 (0.16, 0.63) | 0.49 (0.17, 0.90) | 0.38 (0.17, 0.77) |
| Serum albumin, g/L | 43.4±4.1 | 42.4±4.2 | 42.9±4.1 |
| SCr, μmol/L | 61.9 (54.9, 74.4) | 61.0 (54.0, 74.3) | 61.4 (54.8, 74.3) |
| eGFR, ml/min per 1.73 m2, n (%) | |||
| ≥90 | 94 (81.0) | 72 (80.0) | 166 (80.6) |
| ≥60 to <90 | 18 (15.5) | 15 (16.7) | 33 (16.0) |
| ≥30 to <60 | 3 (2.6) | 3 (3.3) | 6 (2.9) |
| <30 | 1 (0.9) | 0 (0) | 1 (0.5) |
| Serum C3, mg/dl | 85.05 (74.20, 105.00) | 80.70 (69.60, 94.60) | 82.00 (72.20, 100.00) |
| Serum C4, mg/dl | 16.55 (12.20, 21.30) | 15.60 (12.00, 19.30) | 16.00 (12.10, 20.95) |
| Hemoglobin, g/L | 118.0 (110.5, 126.5) | 121.5 (112.0, 130.0) | 119.0 (111.0, 128.0) |
| Anti-dsDNA positive rate, n (%) | 29/115 (25.2) | 24/83 (28.9) | 53/198 (26.8) |
| Renal tubular function | |||
| NAG, U/g creatinine | 5.53 (3.50, 9.80) | 4.80 (4.19, 5.81) | 5.30 (3.50, 9.60) |
| RBP, mg/L | 0.35 (0.20, 0.50) | 0.53 (0.42, 0.80) | 0.40 (0.20, 0.72) |
Data are expressed as numbers (%), medians (25th, 75th percentiles), or means (SD). Reference ranges were as follows: urinary protein, ≤0.4 g/24 h; serum albumin, 35–55 g/L; SCr, men: 45–110 μmol/L (0.51–1.24 mg/dl) and women: 45–93 μmol/L (0.51–1.05 mg/dl); eGFR, 90–120 ml/min per 1.73 m2; hemoglobin, 130–175 g/L (men) and 115–150 g/L (women); serum C3, 80–180 mg/dl; serum C4, 10–40 mg/dl; NAG, ≤16.5 U/g creatinine; RBP, ≤0.5 mg/L. Anti-dsDNA, antidouble-stranded DNA.
a
P<0.05.